Overview

Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Status:
Active, not recruiting

Trial end date:
2021-02-01

Target enrollment:

Participant gender:

Summary

This pilot early phase I trial studies talazoparib to determine if certain characteristics of the deoxyribonucleic acid (DNA) affect how the disease responds to therapy in patients with ovarian, fallopian tube, or primary peritoneal cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Studying samples of tissue in the laboratory from patients receiving talazoparib may help doctors learn more about the effects of talazoparib on cells and may help doctors understand how well patients respond to treatment.

Phase:

Early Phase 1

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborators:

BioMarin Pharmaceutical
National Cancer Institute (NCI)

Treatments:

Talazoparib